Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 8/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888406 | 0.84 | CYP1A2 (0.61) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL781759 | 0.80 | CA1 (0.45) | CYP1A2CYP2C19CA2F2PRSS1 | |
| SCHEMBL12200891 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL9288054 | 0.77 | CYP1A2 (0.53) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL9287368 | 0.77 | CA2 (0.54) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12603022 | 0.76 | CA2 (0.65) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12832696 | 0.76 | CYP1A2 (0.58) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL13274117 | 0.76 | CYP1A2 (0.71) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL1645476 | 0.76 | CA2 (0.52) | CYP1A2CYP2C19HTTHIF1ATDP1 | |
| SCHEMBL12760595 | 0.76 | CA2 (0.59) | CYP1A2CYP2C19HTTHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | HCCS, XPO5, DHX15 | CYP1A2 596/4885CYP2C19 1355/4885HTT 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.